You are about to leave the Clinical Value website now.


The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

Quick Summary

The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. NGS CGPs have been incorporated into clinical practice to improve patient outcomes by identifying actionable drug targets. To integrate NGS CGPs and faciliate the implementation of precision medicine into clinical practice, multi-disciplinary Molecular Tumour Boards (MTBs) have been established, and enable the timely referral of patients to genomically stratified clinical trials

In 2018, the University of Hong Kong (HKU) and Hong Kong Sanatorium & Hospital (HKSH) established the HKU-HKSH Multi-disciplinary MTB to advance precision oncology in Hong Kong. A multicenter retrospective clinical outcome analysis was conducted for patients with advanced solid cancers presented at the HKU-HKSH-MTB for review and treatment recommendations. The primary objective of the study was to demonstrate the survival impact of a comprehensively curated real-world retrospective MTB dataset to facilitate the management of patients with cancer in the era of precision oncology.

You May Also Like

19 May 2023

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Read More
19 May 2023

National Comprehensive Cancer Network (NCCN) guidelines for lung cancer

The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care. Access the…

Read More
13 May 2024

No woman left behind: Increasing access to testing for cervical cancer elimination

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.